| Title : 1,4-Substituted 4-(1H)-pyridylene-hydrazone-type inhibitors of AChE, BCHE, and amyloid-beta aggregation crossing the blood-brain barrier - Prinz_2013_Eur.J.Pharm.Sci_49_603 |
| Author(s) : Prinz M , Parlar S , Bayraktar G , Alptuzun V , Erciyas E , Fallarero A , Karlsson D , Vuorela P , Burek M , Forster C , Turunc E , Armagan G , Yalcin A , Schiller C , Leuner K , Krug M , Sotriffer CA , Holzgrabe U |
| Ref : Eur J Pharm Sci , 49 :603 , 2013 |
|
Abstract :
Given the fundamentally multifactorial character of Alzheimer's disease (AD), addressing more than one target for disease modification or therapy is expected to be highly advantageous. Here, following the cholinergic hypothesis, we aimed to inhibit both acetyl- and butyrylcholinesterase (AChE and BCHE) in order to increase the concentration of acetylcholine in the synaptic cleft. In addition, the formation of the amyloid beta fibrils should be inhibited and already preformed fibrils should be destroyed. Based on a recently identified AChE inhibitor with a 1,4-substituted 4-(1H)-pyridylene-hydrazone skeleton, a substance library has been generated and tested for inhibition of AChE, BCHE, and fibril formation. Blood-brain barrier mobility was ensured by a transwell assay. Whereas the p-nitrosubstituted compound 18C shows an anti-AChE activity in the nanomolar range of concentration (IC50=90nM), the bisnaphthyl substituted compound 20L was found to be the best overall inhibitor of AChE/BCHE and enhances the fibril destruction. |
| PubMedSearch : Prinz_2013_Eur.J.Pharm.Sci_49_603 |
| PubMedID: 23643737 |
Prinz M, Parlar S, Bayraktar G, Alptuzun V, Erciyas E, Fallarero A, Karlsson D, Vuorela P, Burek M, Forster C, Turunc E, Armagan G, Yalcin A, Schiller C, Leuner K, Krug M, Sotriffer CA, Holzgrabe U (2013)
1,4-Substituted 4-(1H)-pyridylene-hydrazone-type inhibitors of AChE, BCHE, and amyloid-beta aggregation crossing the blood-brain barrier
Eur J Pharm Sci
49 :603
Prinz M, Parlar S, Bayraktar G, Alptuzun V, Erciyas E, Fallarero A, Karlsson D, Vuorela P, Burek M, Forster C, Turunc E, Armagan G, Yalcin A, Schiller C, Leuner K, Krug M, Sotriffer CA, Holzgrabe U (2013)
Eur J Pharm Sci
49 :603